

Thank you for attending our live and archived webcast,



Promoting Successful Tobacco Cessation: Treatment Recommendations & Systems Changes for CHCs



Hosted by Community Health Association of Mountain/Plains States (CHAMPS)

Sponsored by Colorado Community Managed Care Network (CCMCN) CHC Tobacco Cessation Program

Presented by Dr. Jeffrey J. Cain on Wednesday, March 28, 2007

Supplementary Information Packet

Contents:

- Learning Objectives
- AAFP, Biography of Dr. Jeffrey Cain, and Description of CHAMPS & CCMCN CHC Tobacco Cessation Program
- Presentation Slides
- o Guideline for Tobacco Cessation and Secondhand Smoke Exposure

Learning Objectives

Through this presentation, participants will be able to:

- 1. Understand the principles of effective clinic tobacco cessation.
- 2. Appropriately prescribe tobacco cessation aids.
- 3. Promote system-wide comprehensive approaches to successful tobacco cessation.
- 4. Utilize community resources and tools to promote tobacco cessation in their clinics.

AAFP

This live webcast has been reviewed and is acceptable for up to 1.5 Prescribed credits by the American Academy of Family Physicians (AAFP). Application for 1.5 hours of Prescribed CME credit for the archived version of this webcast will be filed immediately after the live event. Jeffrey Cain has indicated that he has no relationships to disclose relating to the subject matter of his presentation. The AAFP invites comments on any activity that has been approved for AAFP CME credit. Please forward your comments on the quality of this activity to cmecomment@aafp.org.


Biography of Dr. Jeffrey Cain


Jeffrey J. Cain, MD, is an Assistant Professor at the University of Colorado Health Sciences Center and Chief of Family Medicine at the Children's Hospital in Denver, Colorado. He received his Doctor of Medicine at Oregon Health Sciences University in Portland, is board certified by the American Board of Family Practice, and is a Fellow in the American Academy of Family Physicians. Dr. Cain provides extensive expertise in tobacco cessation, and is the founder and current president of TAR WARS, an award-winning national children's tobacco free education project. Dr. Cain currently sits on the boards of numerous organizations, including the Colorado Multiple Institutional Review Board, the Colorado Children's Immunization Coalition, the Colorado Coalition of Working Amputees, and the Group to Alleviate Smoking Pollution. He is an experienced teacher and presenter with numerous publications addressing topics including tobacco education, vaccinations, and disability insurance, and in 2006 Dr. Cain received a First Place Research Presentation Award from the AAFP Scientific Assembly.


Description of CHAMPS & CCMCN CHC Tobacco Cessation Program


CHAMPS, the Community Health Association of Mountain/Plains States, is the Region VIII Primary Care Association, a non-profit organization dedicated to serving Region VIII Community, Migrant, and Homeless Health Centers (CHCs) as well as Region VIII State Primary Care Associations. Currently, CHAMPS programs and services focus on education and training, collaboration and networking, policy and funding communications, and the collection and dissemination of regional data. For more information, please visit http://www.champsonline.org or call (303) 861-5165.


Colorado Community Managed Care Network (CCMCN) is a network of 12 Colorado Community Health Centers with 60 clinic sites partnering to provide health care quality improvement in the state. After a year of intensive planning and funding from the Colorado Clinical Guidelines Collaborative and the State Tobacco Education and Prevention Program, CCMCN is implementing a comprehensive, system-wide, evidence-based CHC Tobacco Cessation Program by working with CHCs to address their patient population's needs and unique attributes. CCMCN is committed to implementing this program with the long-term goal of improving clinical outcomes and quality of life for CHC patients. It is CCMCN's hope that this unique approach will be expanded to all CHCs in Colorado and will influence other providers, community resources, and individuals, and subsequently reflect a "best practice" intervention for successfully promoting tobacco cessation and reducing the detrimental effects of environmental tobacco smoke especially in underserved and uninsured patient populations. Please contact heather@cchn.org for more information about CCMCN's CHC Tobacco Cessation Program.





















































































































































































Guideline for Tobacco Cessation and Secondhand Smoke Exposure

- Integrate interventions for tobacco cessation and secondhand smoke exposure into every interaction with the patient by using the 5As approach.
- Utilize a combination of behavioral change coaching (including the Colorado QuitLine) and pharmacotherapy treatments for the highest rates of abstinence success.
- Exposure to secondhand smoke is a significant health risk to the general public, especially children, and the establishment of smoke-free environments should be encouraged.
- Evidence shows patients are more likely to quit when their clinician tells them to even a two to three minute clinician intervention has been shown to be effective.

STATE TOBACCO EDUCATION & PREVENTION PARTNERSHIP

Tobacco dependence and use (current or former) is a chronic relapsing condition that requires repeated interventions and a systematic approach.



ASK

- Ask every patient at every encounter if they currently smoke or have ever used any form of tobacco.
- Ask patient or parent of patient if smoking occurs in the home or car (secondhand smoke exposure).
- If patient recently quit using tobacco, reassess abstinence status, address possible relapse, and congratulate on success.

ADVISE

- Urge every tobacco user to quit smoking with clear strong personalized health messages about the benefits of quitting.
- Discuss the health risks of secondhand smoke exposure on household members, especially children, and advise them to smoke outside.

ASSESS

- Determine the willingness to make a quit attempt within the next 30 days.
- AGREEMENT: collaboratively set specific quit goals and address barriers (e.g.: weight gain, fear of failure).
- If not ready to quit, use motivational interventions of encouragement, information and support, recommend to smoke outside, and offer futher help as they consider a quit attempt.

ASSIST

- REFER to the Colorado QuitLine at 1.800.QUIT.NOW (1.800.784.8669) and/or
- Provide positive practical behavioral coaching as part of a guit plan.
- Recommend tailored pharmacotherapy treatments (see reverse side).
- Discuss cessation tips: set a quit date, create smoke-free environments, avoid high risk situations, identify triggers, and suggest social supports.
- Provide self-help materials for cessation and reducing secondhand smoke exposure.

ARRANGE

- Schedule a follow-up contact within the first week after the quit date and a second follow-up contact within the first month.
- Monitor for relapse; if relapse occurs, identify causes and plan next quit attempt.
- Continue to support smoke-free home and car environments.
- Congratulate successes!

Additional Resources:

- FOR COMPREHENSIVE TOBACCO GUIDELINE and COLORADO QUITLINE FAX REFERRAL FORM: www.coloradoguidelines.org/tobacco
- To order free office toolkits and materials: www.STEPPitems.com
- Colorado QuitLine: 1.800.QUIT.NOW (1.800.784.8669)

For important updates, special clinical considerations, additional information, and copies of the guideline email CCGC at tobaccoinfo@coloradoguidelines.org OR call 720.297.1681 OR 866.401.2092 (toll free).

References:

- American Family Physician Vol 74, No 2 July 2006
- Treating Tobacco Use and Dependence; US Department of Health and Human Services Public Health Service, June 2000
- The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General, June 2006

This guideline is designed to assist clinicians in the management of patients with tobacco use and/or secondhand smoke exposure. This guideline is not intended to replace a clinician's judgment or establish a protocol for all patients with a particular condition.

1-800-QUIT-NOW 1-800-784-8669

Pharmacotherapy Treatments: Smoking Cessation Drug Classification and Dosages

Tips to use in tobacco cessation efforts:

Tobacco use is to be approached as a chronic relapsing condition.

If limited on time, Ask, Advise, and Refer to the Colorado QuitLine (1.800.QUIT.NOW). The average smoker has 4-7 attempts before successful abstinence. Combination therapy of >1 form of Nicotine Replacement Therapy (NRT) or NRT + Zyban

Adverse Side Effects/Treatment Tips (• = possible side effects) These are general categories; individual patient reactions may vary.

Precautions (Ø=contraindicated) Consult package insert for full list of precautions, contraindications, use in pediatrics, and drug interactions.

can increase long-term quit rates.

	Category	Drugs	Recommended Dosage	Recommended Duration	Relative Cost Index: 1ppd = \$\$ (av \$120/mo)	Jaw pain/mouth or throat soreness; thr nasal/ mouth irritati	Dry mouth, zerostol	Orthostasis possib	Local skin reaction	Insomnia, abnorma change in dreams	Headache	Gl: nausea, gas, dy pepsia, constipatio	Sedation, drowsine	Recent Myocardial In tion, severe arrhythm unstable angina	Patients with denta problems or TMJ syndrome	Patients w/ seizure disorders, bulimia or anorexia nervosa (ez disorders)	Patients with bipola and schizophrenia; recent MAO use	Suicidal Risk: Black Box Warning	Pregnancy (weigh rivs. benefit)
	NRT (nicotine replacement therapy)	Nicotine Patch/transdermal (NicoDerm CQ, Habitrol, Nicotrol)	> 10 cigs/day: use 21 mg/24 hrs for 6-8 wks, then 14 mg/24 hrs for 2-4 weeks, then 7mg/24 hrs for 2-4 weeks < 10 cigs/day: use 15 mg/16 hrs for 6 weeks	up to 10 weeks	OTC \$ 2 months available free from QuitLine with program enrollment				•	•	•	•		Ø					Cat D
		Nicotine Gum (Nicorette)	1-24 cigs/day: 2 mg gum (every 1- 2 hrs up to 24 pieces/day) 25+ cigs/day: 4 mg gum (every 1- 2 hrs up to 24 pieces/day) No food or drink 15 minutes before use	1-24 cigs/day: 2 mg gum (every 1- 2 hrs up to 24 pieces/day) 25+ cigs/day: 4 mg gum (every 1- 2 hrs up to 24 pieces/day)	OTC \$\$\$	•				•		•		Ø	Ø				Cat C
First Line		Nicotine Lozenge (Commit)	2 mg for those who smoke their first cigarette more than 30 min after waking 4 mg for those who smoke their first cigarette within 30 min of waking No food or drink 15 minutes before use	up to 12 weeks: wks 1- 6: 1 loz/ 1-2 hrs wks 7-9: 1 loz/ 2-4 hrs wk 10-12: 1 loz/ 4-8 hrs	OTC \$\$	•					•	•		Ø					Cat D
		Nicotine Oral Inhaler (Nicotrol Inhaler)	6-16 cartridges/day; puff each cartidge for up to 20 minutes Each cartridge 4 mg 10 puffs inhaler=1 puff cigarette	6-16 cartridges/day; puff each cartidge for up to 20 minutes Each cartridge 4 mg	prescription \$\$	•					•			Ø					Cat D
		Nicotine Nasal Spray (Nicotrol NS)	8-40 sprays/day: 1 dose = 1 spray/ nostril 1-2 doses/ hr (maximum 5 doses/hr or < 40 doses/day)	Up to 3 - 6 months	prescription \$\$	•						•		Ø					Cat D
	Medications	Bupropion SR (Zyban)	150 mg/day for 3 days, then 150 mg/day BID from day 4 to end of treatment (begin treatment 1-2 weeks pre-quit)	Up to 12 weeks Maintenance up to 6 months	prescription \$\$					•	•					Ø	Ø	Ø	Cat C
		Varenicline (Chantix)	0.5 mg/day on days 1-3, 0.5 mg BID on days 4-7, then 1 mg BID from day 8 to end of treatment (begin treatment 7 days pre-quit date)	12 weeks treatment additional 12 weeks to enhance cessation	prescription \$\$					•	•	•							Cat C
nd Line	Drugs not approved for smoking cessation by the FDA	Clonidine (Catapres)	0.10 mg/day for wk 1, increasing by 0.1 mg/day each week as needed up to .75 mg/day OR patch/week	Up to 10 weeks	prescription \$		•	•			•		•	Ø		Ø			Cat C
Second	by the LDA	Nortriptyline (Aventyl, Pamelor)	25 mg/day for week 1, increasing to 75 -100 mg/day	Up to 12 weeks	prescription \$		•	•					•	Ø		Ø	Ø	Ø	Cat C

References:

The Medical Letter Vol 48 Aug 2006 American Family Physician Vol 74, No 2 July 2006 Treating Tobacco Use and Dependence; US Department of Health and Human Services Public Health Service, June 2000

FDA package inserts

For important updates, special clinical considerations, and effectiveness information, visit www.coloradoguidelines.org/tobacco

2nd revision: 2/2007 1st revision: 11/2004 Original: 9/2002